CA
ABBV icon

Callahan Advisors’s AbbVie ABBV Stock Holding History

Callahan Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.15M Sell
5,309
-229
-4% -$50.8K 0.1% 108
2025
Q4 		$1.27M Sell
5,538
-371
-6% -$84.5K 0.1% 105
2025
Q3 		$1.37M Buy
5,909
+172
+3% +$35K 0.12% 98
2025
Q2 		$1.06M Buy
5,737
+9
+0.2% +$1.67K 0.1% 105
2025
Q1 		$1.2M Buy
5,728
+609
+12% +$118K 0.11% 105
2024
Q4 		$910K Buy
5,119
+414
+9% +$76.1K 0.09% 114
2024
Q3 		$929K Sell
4,705
-3
-0.1% -$560 0.09% 103
2024
Q2 		$807K Buy
4,708
+5
+0.1% +$828 0.08% 107
2024
Q1 		$856K Buy
4,703
+4
+0.1% +$689 0.09% 101
2023
Q4 		$728K Buy
4,699
+6
+0.1% +$875 0.08% 101
2023
Q3 		$700K Sell
4,693
-2,253
-32% -$331K 0.09% 102
2023
Q2 		$936K Sell
6,946
-27,362
-80% -$4.01M 0.11% 92
2023
Q1 		$5.47M Hold
34,308
– – 0.71% 49
2022
Q4 		$5.54M Sell
34,308
-195
-0.6% -$29.9K 0.76% 48
2022
Q3 		$4.63M Sell
34,503
-74
-0.2% -$10.6K 0.67% 52
2022
Q2 		$5.3M Buy
34,577
+385
+1% +$58.8K 0.7% 52
2022
Q1 		$5.54M Buy
34,192
+115
+0.3% +$16.7K 0.63% 53
2021
Q4 		$4.61M Sell
34,077
-3
-0% -$354 0.52% 58
2021
Q3 		$3.68M Sell
34,080
-142
-0.4% -$16.2K 0.46% 60
2021
Q2 		$3.85M Buy
34,222
+50
+0.1% +$5.63K 0.49% 58
2021
Q1 		$3.7M Buy
34,172
+100
+0.3% +$10.7K 0.5% 58
2020
Q4 		$3.65M Sell
34,072
-69
-0.2% -$6.63K 0.53% 54
2020
Q3 		$2.99M Buy
34,141
+1,000
+3% +$94.1K 0.49% 53
2020
Q2 		$3.25M Buy
33,141
+10,854
+49% +$956K 0.58% 48
2020
Q1 		$1.7M Sell
22,287
-25
-0.1% -$2.13K 0.36% 62
2019
Q4 		$1.98M Buy
22,312
+34
+0.2% +$2.82K 0.32% 67
2019
Q3 		$1.69M Buy
22,278
+1,100
+5% +$75.4K 0.29% 70
2019
Q2 		$1.54M Buy
21,178
+10,100
+91% +$794K 0.28% 71
2019
Q1 		$893K Sell
11,078
-750
-6% -$61.4K 0.17% 90
2018
Q4 		$1.09M Hold
11,828
– – 0.23% 79
2018
Q3 		$1.12M Buy
11,828
+179
+2% +$17K 0.21% 85
2018
Q2 		$1.08M Hold
11,649
– – 0.21% 81
2018
Q1 		$1.1M Hold
11,649
– – 0.23% 79
2017
Q4 		$1.13M Buy
11,649
+350
+3% +$33K 0.22% 80
2017
Q3 		$1M Hold
11,299
– – 0.21% 80
2017
Q2 		$819K Hold
11,299
– – 0.18% 84
2017
Q1 		$736K Hold
11,299
– – 0.17% 82
2016
Q4 		$708K Hold
11,299
– – 0.17% 83
2016
Q3 		$713K Hold
11,299
– – 0.18% 79
2016
Q2 		$700K Hold
11,299
– – 0.18% 78
2016
Q1 		$645K Sell
11,299
-270
-2% -$15K 0.18% 80
2015
Q4 		$685K Hold
11,569
– – 0.2% 79
2015
Q3 		$629K Hold
11,569
– – 0.19% 80
2015
Q2 		$777K Buy
11,569
+250
+2% +$16.3K 0.22% 83
2015
Q1 		$663K Buy
11,319
+200
+2% +$12.1K 0.19% 84
2014
Q4 		$728K Buy
11,119
+299
+3% +$18.9K 0.21% 84
2014
Q3 		$625K Hold
10,820
– – 0.19% 87
2014
Q2 		$611K Hold
10,820
– – 0.19% 88
2014
Q1 		$556K Sell
10,820
-1,500
-12% -$75.8K 0.19% 87
2013
Q4 		$651K Buy
12,320
+20
+0.2% +$983 0.23% 83
2013
Q3 		$550K Hold
12,300
– – 0.21% 85
2013
Q2 		$508K Buy
+12,300
New +$538K 0.21% 85

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Callahan Advisors's ABBV Position: Q1 2026 in Review

Callahan Advisors reduced its AbbVie (ABBV) stake by 4.1% in Q1 2026, selling an estimated $50.8K and leaving 5,309 shares worth $1.15M. The position accounts for 0.1% of the portfolio, ranked #108.

Callahan Advisors first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.54M in Q4 2022. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Callahan Advisors held 5,309 shares of AbbVie worth $1.15M as of Q1 2026.
  • Callahan Advisors sold 229 AbbVie shares in Q1 2026, an estimated $50.8K.
  • AbbVie made up 0.1% of Callahan Advisors's portfolio in Q1 2026, its #108 holding.
  • Callahan Advisors first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Callahan Advisors's AbbVie position peaked at $5.54M in Q4 2022.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Callahan Advisors's 13F filing for Q1 2026, filed 12 May 2026.